Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series

J Am Acad Dermatol. 2020 Dec;83(6):1813-1814. doi: 10.1016/j.jaad.2020.04.025. Epub 2020 Apr 11.

Authors

Asfandyar Mufti¹, Khalad Maliyar², Laura Walton³, Ronald Vender⁴, Jensen Yeung⁵

Affiliations

¹ Division of Dermatology, Toronto, Ontario, Canada.
² Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
³ Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada.
⁴ Department of Dermatology, McMaster University, Hamilton, Ontario, Canada.
⁵ Division of Dermatology, Toronto, Ontario, Canada; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: jensen.yeung@utoronto.ca.

PMID: 32289394
DOI: 10.1016/j.jaad.2020.04.025

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / adverse effects
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Injections, Subcutaneous
Male
Middle Aged
Psoriasis / diagnosis
Psoriasis / drug therapy*
Retrospective Studies
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
guselkumab